Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
REVENUES:
Grant revenue	$ 529	$ 1,941	$ 1,278	$ 2,266
Royalties from product sales and license fees	140	91	226	227
Subscription and advertisement revenues		333		572
Sale of research products and services	110	182	203	182
Total revenues	779	2,547	1,707	3,247
Cost of sales	(107)	(106)	(175)	(215)
Gross profit	672	2,441	1,532	3,032
OPERATING EXPENSES:
Research and development	5,235	6,358	10,196	12,293
Acquired in-process research and development				800
General and administrative	6,258	5,227	14,918	11,163
Total operating expenses	11,493	11,585	25,114	24,256
Loss from operations	(10,821)	(9,144)	(23,582)	(21,224)
OTHER INCOME/(EXPENSES):
Interest income, net	437	52	879	105
Gain on sale of equity method investment in Ascendance				3,215
Unrealized (loss) gain on marketable equity securities	(607)	397	1,324	612
Unrealized gain on warrant liability	234	460	271	351
Other (expense) income, net	882	(839)	1,688	(1,014)
Total other (expense) income, net	(20,479)	4,498	27,194	(47,120)
(LOSS)/INCOME BEFORE INCOME TAXES	(31,300)	(4,646)	3,612	(68,344)
Deferred income tax benefit	1,248		5,632
NET (LOSS)/INCOME	(30,052)	(4,646)	9,244	(68,344)
Net loss attributable to noncontrolling interest	20	431	34	581
NET (LOSS)/INCOME ATTRIBUTABLE TO BIOTIME, INC.	$ (30,032)	$ (4,215)	$ 9,278	$ (67,763)
NET (LOSS)/INCOME PER COMMON SHARE:
BASIC	$ (0.20)	$ (0.03)	$ 0.07	$ (0.53)
DILUTED	$ (0.20)	$ (0.03)	$ 0.07	$ (0.53)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC	149,582,000	126,873,000	141,270,000	126,871,000
DILUTED	149,582,000	126,873,000	141,270,000	126,871,000
OncoCyte Corporation [Member]
OTHER INCOME/(EXPENSES):
(Loss) gain on equity method investment	$ (21,425)	$ 6,603	$ 16,288	$ (30,816)
Asterias Biotherapeutics [Member]
OTHER INCOME/(EXPENSES):
(Loss) gain on equity method investment		$ (2,175)	$ 6,744	$ (19,573)